Back to results

CompletedPhase 3

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

NCT01191944

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

248.671.86004 Boehringer Ingelheim Investigational Site

Beijing, China

+19 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2010-08
Enrollment: 475 participants
Sponsor: Boehringer Ingelheim
Purpose: treatment

Locations (20)

248.671.86004 Boehringer Ingelheim Investigational SiteBeijing, China
248.671.86006 Boehringer Ingelheim Investigational SiteBeijing, China
248.671.86007 Boehringer Ingelheim Investigational SiteBeijing, China
248.671.86020 Boehringer Ingelheim Investigational SiteBeijing, China
248.671.86012 Boehringer Ingelheim Investigational SiteChengdu, China
248.671.86013 Boehringer Ingelheim Investigational SiteChongqing, China
248.671.86014 Boehringer Ingelheim Investigational SiteChongqing, China
248.671.86008 Boehringer Ingelheim Investigational SiteGuangzhou, China
248.671.86009 Boehringer Ingelheim Investigational SiteGuangzhou, China
248.671.86017 Boehringer Ingelheim Investigational SiteHangzhou, China
248.671.86018 Boehringer Ingelheim Investigational SiteHangzhou, China
248.671.86005 Boehringer Ingelheim Investigational SiteJinan, China
248.671.86002 Boehringer Ingelheim Investigational SiteNanjing, China
248.671.86001 Boehringer Ingelheim Investigational SiteShanghai, China
248.671.86003 Boehringer Ingelheim Investigational SiteShanghai, China
248.671.86010 Boehringer Ingelheim Investigational SiteShanghai, China
248.671.86011 Boehringer Ingelheim Investigational SiteShenyang, China
248.671.86019 Boehringer Ingelheim Investigational SiteSuzhou, China
248.671.86015 Boehringer Ingelheim Investigational SiteWuhan, China
248.671.86016 Boehringer Ingelheim Investigational SiteWuhan, China

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients — TrialFind